drugset
drugset / Trial / NCT06517511

Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)

NCT06517511 ↗

Phase 2 Recruiting 42 enrolled Sun Yat-sen University Fudan University · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective, single-arm, multi-center, phase II clinical trial to evaluate the efficacy and safety of selinexor in combination with R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone) followed by selinexor maintenance for untreated TP53-mutated diffuse large B-cell lymphoma (DLBCL) patients.

Timeline

Start
2024-08-01
Primary completion
2027-01
Completion
2028-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Selinexor Other / unclassified 60 mg Oral
Background Cyclophosphamide Other / unclassified — —
Background Doxorubicin Other / unclassified — —
Background Prednisone Other / unclassified — —
Background Rituximab Monoclonal antibody — —
Background Vincristine Small molecule — —

Indications

diffuse large B-cell lymphoma